Entry into a Material Definitive Agreement
Show detailsHide details
1.01 Entry into a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 9.01 Financial Statements and Exhibits
Pluri Inc.
A biotechnology company in Haifa, Israel, that grows human, animal, and plant cells at industrial scale using a three-dimensional cell-expansion platform. Its placenta-derived PLX cell therapies target inflammatory and muscle conditions, while the same technology also feeds cultivated-meat and agricultural projects. Founded from stem-cell patents developed during founder Shai Meretzki's PhD at the Technion, it was long known as Pluristem Therapeutics before shortening its name to Pluri in 2022 — a nod to "pluripotent" cells.
1.01 Entry into a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 9.01 Financial Statements and Exhibits
8.01 Other Events
8.01 Other Events
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1.01 Entry into a Material Definitive Agreement · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
8.01 Other Events
1.01 Entry into a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 9.01 Financial Statements and Exhibits
8.01 Other Events